医学
FOXP3型
肿瘤浸润淋巴细胞
结直肠癌
CD8型
肿瘤科
内科学
临床终点
放射治疗
免疫系统
肿瘤微环境
胃肠病学
癌症
临床试验
免疫学
作者
Céline Mirjolet,Céline Charon‐Barra,Sylvain Ladoire,Francine Arbez‐Gindre,Aurélie Bertaut,François Ghiringhelli,Agnès Leroux,D. Peiffert,Christophe Borg,J.F. Bosset,G. Créhange
出处
期刊:OncoImmunology
[Landes Bioscience]
日期:2017-10-30
卷期号:7 (3): e1396402-e1396402
被引量:39
标识
DOI:10.1080/2162402x.2017.1396402
摘要
Introduction: Some studies have suggested that baseline tumor-infiltrating-lymphocytes (TILs), such as CD8+ and FoxP3+ T-cells, may be associated with a better prognosis in colorectal cancer. We sought to investigate modulation of the immune response by preoperative radiotherapy (preopRT) and its impact on survival in locally advanced rectal cancer (LARC). Materials & Methods: We analyzed data for 237 patients with LARC who received RT. Density of TILS (CD8+ and FoxP3+) in intraepithelial (iTILs) and stromal compartments (sTILs) were evaluated from surgery pathological specimens and biopsies performed at baseline. The primary endpoint was to assess the impact of infiltration of the tumor or tumor site after preopRT on progression-free survival (PFS) and overall survival (OS). Secondary endpoints were the impact of dose fractionation scheme on TILs. Results: In univariate analysis, several factors significantly correlated (p<0.05) with PFS and/or OS (T-stage, M-stage, the delay between RT and surgery). A high level of post-treatment FoxP3+ TIL density correlated significantly with a better PFS (p = 0.007). In multivariate analysis, a decrease in the CD8+/FoxP3+ iTILs ratio after preopRT correlated with better PFS and OS (p = 0.049 and p = 0.024, respectively). More particularly, patients with a delta CD8+/FoxP3+ <-3.8 had better PFS and OS. Interestingly, the dose fractionation scheme significantly influenced the CD8+/FoxP3+ ratio after treatment (p = 0.027) with a lower ratio with hypofractionated RT (≥2 Gy). Conclusion: Patients with LARC who had a significant decrease in the CD8+/FoxP3+ ratio after preopRT were more likely to live longer. This ratio needs to be validated prospectively to guide physicians in adjuvant treatment decision-making.
科研通智能强力驱动
Strongly Powered by AbleSci AI